Logo

Amgen Presents Results of Lumakras (sotorasib) + Vectibix (panitumumab) in P-Ib/II CodeBreaK 101 study for KRAS G12C-Mutated Colorectal Cancer at ESMO21 2021

Share this

Amgen Presents Results of Lumakras (sotorasib) + Vectibix (panitumumab) in P-Ib/II CodeBreaK 101 study for KRAS G12C-Mutated Colorectal Cancer at ESMO21 2021

Shots:

  • The P-Ib/II CodeBreaK 101 study evaluates Lumakras + Vectibix in 31 patients with KRAS G12C-mutated advanced CRC
  • The results demonstrated ORR (27%) among 26 patients in the efficacy analysis- DCR (81%)- 33% of patients experienced a response in the expansion cohort- no patients experienced dose-limiting toxicities during the 28 days following initial treatment. The therapy also demonstrated the efficacy and safety
  • Amgen has completed an enrolment in P-III CodeBreaK 200 trial to evaluate sotorasib vs docetaxel in patients with KRAS G12C-mutated NSCLC. Lumakras is also being studied in multiple other solid tumors

  | Ref: PR Newswire | Image: Wall Street Journal

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions